Skip to main content
. 2021 Jan;9(1):34. doi: 10.21037/atm-20-1471

Figure 1.

Figure 1

PFS, OS and objective response in patients treated with ICI (A) in overall cohort; (B) stratified by numbers of metastatic organs; (C) stratified by metastatic sites. ICI, immune checkpoint inhibitor.